Jubilant Pharmova Approves API Business Slump Sale to Jubilant Biosys

    Synopsis:

    Jubilant Pharmova will transfer its API business to subsidiary Jubilant Biosys via a slump sale. The division recorded Rs.609 crore revenue in FY25. Jubilant Pharmova share price dropped 1.74% to Rs.1,125 post-announcement on the BSE..


    Jubilant Pharmova Ltd announced on June 12 that its board has approved the sale and transfer of its active pharmaceutical ingredient (API) business to Jubilant Biosys Ltd, a wholly-owned subsidiary. The transaction will be executed as a slump sale and is expected to be completed by September 1, 2025, subject to regulatory and procedural approvals.

    The sale marks a structural reshuffle within the group, aimed at streamlining operations by transferring the API vertical into a subsidiary focused on global drug discovery services.

    Also read: DCM Shriram to Acquire Hindusthan Specialty Chemicals for Rs. 375 Crore

    Jubilant Pharmova Ltd

    Trade

    969-1.79 (-0.18 %)

    Updated - 24 July 2026
    971.10day high
    DAY HIGH
    950.60day low
    DAY LOW
    57028
    VOLUME (BSE)

    Key Takeaways

    • API division revenue (FY25): Rs.609 crore (8.35% of consolidated revenue).

    • Net worth of API division: Rs.666.5 crore (10.68% of consolidated net worth).

    • Transfer mode: Slump sale, mainly through share issuance.

    • Completion timeline: On or before September 1, 2025.

    • Jubilant Pharmova share price: Closed at Rs.1,125, down 1.74%.

    Also read: Genus Power: GIC Affiliate Plans Rs.650 Crore Stake Sale via Block Deal

    Transaction Structure And Financial Basis

    The deal qualifies as a related party transaction, as Jubilant Biosys is a wholly-owned subsidiary of Jubilant Pharmova. However, the company confirmed the transaction would occur on an arm’s length basis. The sale is not part of any Scheme of Arrangement, and hence Regulation 37A of SEBI Listing Regulations is not applicable.

    The consideration will be determined based on the book value of assets and liabilities of the API division as of the appointed date.

    Business Unit

    Details

    Division Transferred

    API Business

    Revenue (FY25)

    Rs.609 crore

    Net Worth (as of Mar 2025)

    Rs.666.5 crore

    Share of Consolidated Rev.

    8.35%

    Share of Consolidated NW

    10.68%

    Transfer Completion Date

    By September 1, 2025

    Strategic Purpose And Market Reaction

    This internal restructuring allows Jubilant Pharmova to consolidate research-focused businesses under Jubilant Biosys while maintaining group control. By realigning the API vertical into a specialised unit, the company aims to boost operational focus across product categories.

    Following the announcement, Jubilant Pharmova share price declined by Rs.19.90, or 1.74%, on the BSE, closing at Rs.1,125. Despite the dip, the move is viewed as part of the company’s broader strategy to enhance organisational efficiency and business alignment.

    Jubilant Pharmova share price may continue to reflect short-term volatility until the completion of the transaction, depending on regulatory progress and integration outcomes.

    Also read: Oil Prices Soar 11% as Israeli Strikes on Iran Trigger Supply Fears

    Share this article: 

    Published Date : 13 Jun 2025

    Disclaimer :

    Investments in securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.


    The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes. The securities are quoted as an example and not as a recommendation. Past performance is not necessarily a guide to future performance.

    The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and/or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.

    Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.

    BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.



    Content Partner - Dalal Street Investment Journal Wealth Advisory Private Limited



    This article is for educational purposes only and should not be considered investment advice. Market investments are subject to risks. DSIJ Wealth Advisory Private Limited is a SEBI-registered Research Analyst (Reg. No: INH000006396) and Investment Adviser (Reg. No: INA000001142). Please consult your financial adviser before investing. 

    For more disclaimer, check here : https://www.bajajbroking.in/disclaimer

    Read More Blogs

    Our Secure Trading Platforms

    Level up your stock market experience: Scan the QR to download the Bajaj Broking App for effortless investing and trading

    QR code to download Bajaj Broking App

    9 lakh+ Users

    icon-with-text

    4.9 App Rating

    icon-with-text

    4 Languages

    icon-with-text

    ₹7,000 Cr+ MTF Book

    icon-with-text
    banner-icon

    Open Your Free Demat Account

    Enjoy low brokerage on delivery trades

    +91

    |

    Open Your Free Demat Account

    Enjoy low brokerage on delivery trades

    +91

    |